|40.74|| +0.25 / +0.62%|
Chimerix, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel, oral antiviral therapeutics designed to address unmet medical need. Its proprietary lipid technology to unlock the potential of some of the most broad-spectrum antivirals by enhancing their antiviral activity and safety profiles in convenient, orally administered dosing regiments. The company has two nucleotide compounds in clinical development that utilize their proprietary lipid technology. Brincidofovir and CMX157. Chimerix was founded by George R. Painter and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
|M. Michelle Berrey||President, CEO, Director & Chief Medical Officer|
|Timothy W. Trost||Chief Financial Officer, Secretary & Senior VP|
|Hervé Momméja-Marin||Vice President-Clinical Research|
|William Garrett Nichols||Chief Medical Officer|
|Linda M. Richardson||Chief Commercial Officer|